Skip to main content
. 2024 Jan 3;48(1):83–96. doi: 10.4093/dmj.2022.0363

Fig. 6.

Fig. 6.

Schematic diagram illustrating a possible mechanism of the protective effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on cardiovascular disease. Ang II, angiotensin II; Pi, inorganic phosphate; AT1, angiotensin II receptor type 1; AT2, angiotensin II receptor type 2; Erk, extracellular signal-regulated kinase; JNK, c-JUN N-terminal kinase; VSMC, vascular smooth muscle cell; ER, endoplasmic reticulum; Atf4, activating transcription factor 4; Bmp2, bone morphogenic protein 2; Runx2, runtrelated transcription factor-2.